A Year on Compounded Semaglutide: An Honest Account is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
Twelve months in, the most useful thing I can offer is a clear-eyed account rather than a transformation story.
My friend Derek, a 41-year-old electrician in Tulsa, started the same week I did. We compared notes every couple of weeks. By month three he was down nineteen pounds and texting me photos of his scale like a kid at Christmas. I was down fourteen and feeling good about it, but also aware that his experience and mine were already diverging. “Same drug, same starting dose, completely different ride,” he told me over the phone one Saturday in April. That single observation probably captures this whole piece better than anything else I’ll write.
What follows covers the dosing arc, the side-effect curve, the cost ledger, and the parts that didn’t look the way I expected when I started. Compounded semaglutide is not FDA-approved. It is prepared by licensed compounding pharmacies for individual patients under a prescriber’s order, and that framing matters for anyone trying to compare what I went through to what they might experience.
Where I Started, and Why Compounded
I came in at a BMI in the mid-thirties, with a recent A1c reading that put me at the upper edge of prediabetes. The standard branded GLP-1 path wasn’t a reasonable option for me. My commercial insurance plan didn’t list a covered indication that matched my chart, and the cash price on the branded medication sat above twelve hundred dollars per month at my local pharmacy.
I spent about three weeks reading before I committed. The decision was financial and clinical, simultaneously. The active ingredient is the same molecule that appears in the published trial program. The preparation pathway is different. The clinical literature on compounded preparations specifically is thinner than the literature on the branded products. I went in knowing those facts.
See also: Vograce: The Creative Manufacturing Studio Turning Digital Art Into Real-World Merchandise
Titration: The First Twelve Weeks
The standard titration ladder is 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then a continued step up based on tolerance and response. My prescriber used that same ladder. The first injection produced a mild loss of appetite within a day, which I hadn’t expected to feel that quickly. Like flipping a dimmer switch on hunger. The first significant side effect was mild nausea in week two, mostly tied to evenings when I ate too fast.
Weight came off in the first three months at a pace that surprised me. About fourteen pounds in those twelve weeks. The literature on the branded product describes a similar early curve, and my experience tracked it closely.
The Boring Middle (Months Four Through Six)
Months four through six were the part nobody writes about, because there’s not much to say. The dose was steady at 1.0 mg. Weight came off slowly and consistently. I lost about seven additional pounds over those three months, a pace that lined up with what my prescriber had described in advance.
Side effects largely receded. The early nausea had settled into a manageable pattern that mostly involved eating slower and earlier in the evening. The fatigue I’d noticed in month two was gone by month four. Honestly, this stretch felt like taking a daily vitamin. Unremarkable. That’s the point.
The Plateau That Taught Me More Than the Early Weeks
The plateau arrived in month seven, right on schedule. The scale stopped moving for about five weeks. My prescriber and I talked through it on a routine check-in. We chose not to push the dose higher. The decision was clinical, not arbitrary. I was tolerating 1.0 mg well, the early-phase weight loss had been clinically meaningful, and there was no reason to chase a faster curve at the cost of side effects.
Here’s the thing: the plateau broke on its own around week six. I lost three pounds over the next month without any change in dose or diet. That experience taught me more about how this medication actually works than any of the dramatic early weeks did. Weight loss on a GLP-1 agonist is less like draining a bathtub and more like a staircase you can only see from a distance.
The Final Stretch and the Numbers
The last three months were the steadiest. The dose moved up to 1.7 mg in month ten, partly to chase the last several pounds I’d set as a soft goal and partly because my prescriber wanted to see whether the higher dose produced a meaningfully different side-effect profile for me. It didn’t. Nausea remained mild and manageable. I lost an additional six pounds.
At the twelve-month mark, the total was about thirty pounds. That sits on the lower end of published trial averages, and that’s fine. The trials report a distribution, not a single number, and a thirty-pound year-one outcome at a starting BMI in the mid-thirties is a clinically meaningful result. Derek, for the record, finished at thirty-eight pounds. Same molecule, different body.
The Cost Ledger
The total spend across twelve months was just under three thousand dollars for the medication itself. That figure includes the medication, prescriber visits, and periodic lab work the program required. The provider I worked with was HealthRX, which runs a flat-rate model that I found easier to budget against than the variable pricing some other programs use.
For comparison, the cash price on the branded medication at my local pharmacy would have run between fourteen and sixteen thousand dollars across the same twelve months. The two programs aren’t identical in their clinical framing, and that comparison isn’t meant to be an equivalency claim. The molecule is the same. The preparation, the regulatory status, and the supply chain are different.
What I’d Do Over
Three things, if I could rewind.
First, I’d have started with a more structured food protocol in month one. The weight came off quickly enough early on that I didn’t feel pressure to build sustainable habits, and that turned into a real problem in month seven when the plateau hit. The patients I’ve spoken to who built food habits early seem to have an easier time in months six through twelve.
Second, I’d have started lifting weights immediately. I began twice-a-week strength training in month five and wished I’d started in month one. Some of the weight that came off in those early months was lean mass. The published literature has discussed the lean-mass question extensively, and the practical answer involves protein intake and resistance training. Both are easier to build early than to bolt on halfway through.
Third, I’d have asked more questions about the maintenance phase. Most of my early conversations with the prescriber focused on the loss phase. Year two is its own clinical question, and I’m still working through it. Research suggests that long-term outcomes depend more on the maintenance protocol than on the loss-phase protocol. That observation is what year two is going to test for me.
What This Is (and Isn’t)
This is one patient’s twelve-month account. It is not a clinical recommendation, a comparison to the branded products beyond the same-active-ingredient framing, or a suggestion that another patient’s year will look the same as mine.
Compounded semaglutide is not FDA-approved. It is prepared by licensed compounding pharmacies for individual patients under a prescriber’s order. The clinical literature on the branded products remains the strongest available reference for what the molecule does in the body, and that literature is the basis for most clinical decisions in this space.
A reasonable year-one outcome on compounded semaglutide looks like a steady curve, a manageable side-effect profile, and a clinical relationship with a prescriber who treats the patient as a partner in the protocol. Anything that gets sold as faster than that, or cheaper than that, deserves a second look before a deposit.
Frequently Asked Questions
Is compounded semaglutide the same as Ozempic or Wegovy? The active molecule is the same. The manufacturing process, regulatory oversight, and FDA approval status are not. Compounded semaglutide is prepared by licensed compounding pharmacies under a prescriber’s order and is not FDA-approved.
How much does a year of compounded semaglutide typically cost? Costs vary by provider, but my twelve-month total (medication, visits, labs) came in just under three thousand dollars. Branded versions ran fourteen to sixteen thousand at my local pharmacy without insurance coverage.
What side effects should I expect in the first few months? The most common early side effects are mild nausea, reduced appetite, and occasional fatigue. In my experience, these peaked in weeks two through four and largely resolved by month four.
How much weight can I realistically expect to lose in a year? Published trial data on branded semaglutide shows a wide distribution. My thirty-pound result at a starting BMI in the mid-thirties fell on the lower end but was clinically meaningful. Individual results vary significantly.
What happens when I hit a plateau? Plateaus are common and often resolve without a dose change. Mine lasted about five weeks before weight loss resumed at the same dose. The key is working with a prescriber who treats a plateau as a normal phase, not a reason to immediately escalate.
Do I need to exercise while taking semaglutide? Exercise isn’t strictly required for weight loss on semaglutide, but resistance training and adequate protein intake are important for preserving lean mass. Starting early is better than adding it mid-protocol.
What should I look for in a compounded semaglutide provider? Transparent pricing, a structured titration plan, regular check-ins, and lab monitoring. A flat-rate model made budgeting easier for me than programs with variable pricing or hidden fees.
